Compounds > lanreotide acetate
Page last updated: 2024-12-06

lanreotide acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Lanreotide acetate is a synthetic octapeptide analog of somatostatin. It is a potent and long-acting somatostatin receptor agonist with high affinity for somatostatin receptor subtypes 2 and 5. Lanreotide acetate has been shown to effectively inhibit the release of growth hormone, insulin-like growth factor 1, glucagon, and other hormones, including vasoactive intestinal peptide and gastrin. It is used for the treatment of acromegaly, a condition characterized by excessive growth hormone production, and neuroendocrine tumors, such as carcinoid tumors, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and pituitary adenomas. Lanreotide acetate is administered by subcutaneous injection and has a long half-life, allowing for once-monthly or less frequent dosing. It is studied due to its potential for effective treatment of various endocrine disorders, including acromegaly, neuroendocrine tumors, and Cushing's disease. Research focuses on investigating its efficacy, safety, and potential for long-term use. Lanreotide acetate is synthesized through a complex multi-step chemical process involving amino acid coupling, protecting group manipulations, and purification techniques. It is crucial in understanding the mechanism of action of somatostatin analogs and their therapeutic applications.'

Cross-References

ID SourceID
PubMed CID71349
SCHEMBL ID34091
SCHEMBL ID14802383
MeSH IDM0324152

Synonyms (21)

Synonym
gtpl2031
NCGC00181321-01
127984-74-1
L000343
10-(4-aminobutyl)-n-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
SCHEMBL34091
SCHEMBL14802383
DB06791
lanreotide; angiopeptin; 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-l-threoninamide cyclic (2-7)-disulfide; 127984-74-1
3-(2-naphthyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-l-threoninamide cyclic (2-->7)-disulfide
10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-n-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide
3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-l-threoninamide cyclic (2 inverted exclamation marku7)-disulfide acetate
(4s,7s,10s,13r,16s,19s)-13-((1h-indol-3-yl)methyl)-19-((r)-2-amino-3-(naphthalen-2-yl)propanamido)-n-((2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl)-10-(4-aminobutyl)-16-(4-hydroxybenzyl)-7-isopropyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacyclo
PUDHBTGHUJUUFI-UHFFFAOYSA-N
somatuline; lanreotidum; bim 23014c
angiopeptin; 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-l-threoninamide cyclic (2-7)-disulfide acetate;lanreotide
A857302
BS-42393
CFA98474
EN300-26911522
2-({19-[2-amino-3-(naphthalen-2-yl)propanamido]-10-(4-aminobutyl)-16-[(4-hydroxyphenyl)methyl]-13-[(1h-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}formamido)-3-hydroxybutanamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1346311Mouse SST2 receptor (Somatostatin receptors)1998Reviews of physiology, biochemistry and pharmacology, , Volume: 133The elucidation of somatostatin receptor functions: a current view.
AID1346424Human SST2 receptor (Somatostatin receptors)1998European journal of pharmacology, May-08, Volume: 348, Issue:2-3
[125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
AID1346321Rat SST3 receptor (Somatostatin receptors)1998Reviews of physiology, biochemistry and pharmacology, , Volume: 133The elucidation of somatostatin receptor functions: a current view.
AID1346332Human SST3 receptor (Somatostatin receptors)1996Metabolism: clinical and experimental, Aug, Volume: 45, Issue:8 Suppl 1
Binding properties of somatostatin receptor subtypes.
AID1346332Human SST3 receptor (Somatostatin receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, May, Volume: 357, Issue:5
[125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
AID1346413Human SST5 receptor (Somatostatin receptors)1996Metabolism: clinical and experimental, Aug, Volume: 45, Issue:8 Suppl 1
Binding properties of somatostatin receptor subtypes.
AID1346424Human SST2 receptor (Somatostatin receptors)1994Endocrinology, Dec, Volume: 135, Issue:6
Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
AID1346424Human SST2 receptor (Somatostatin receptors)1996Metabolism: clinical and experimental, Aug, Volume: 45, Issue:8 Suppl 1
Binding properties of somatostatin receptor subtypes.
AID1346413Human SST5 receptor (Somatostatin receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, May, Volume: 357, Issue:5
[125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
AID1346420Rat SST5 receptor (Somatostatin receptors)1998Reviews of physiology, biochemistry and pharmacology, , Volume: 133The elucidation of somatostatin receptor functions: a current view.
AID1346424Human SST2 receptor (Somatostatin receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, May, Volume: 357, Issue:5
[125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
AID1346404Mouse SST3 receptor (Somatostatin receptors)1993Molecular pharmacology, Jun, Volume: 43, Issue:6
Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides.
AID1346419Rat SST2 receptor (Somatostatin receptors)1998Reviews of physiology, biochemistry and pharmacology, , Volume: 133The elucidation of somatostatin receptor functions: a current view.
AID1346332Human SST3 receptor (Somatostatin receptors)1994Endocrinology, Dec, Volume: 135, Issue:6
Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
AID1346424Human SST2 receptor (Somatostatin receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Nov, Volume: 360, Issue:5
Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
AID1346413Human SST5 receptor (Somatostatin receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Nov, Volume: 360, Issue:5
Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
AID1346413Human SST5 receptor (Somatostatin receptors)1994Endocrinology, Dec, Volume: 135, Issue:6
Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).
AID1346413Human SST5 receptor (Somatostatin receptors)1998Reviews of physiology, biochemistry and pharmacology, , Volume: 133The elucidation of somatostatin receptor functions: a current view.
AID1346332Human SST3 receptor (Somatostatin receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Nov, Volume: 360, Issue:5
Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
AID1346413Human SST5 receptor (Somatostatin receptors)1998European journal of pharmacology, May-08, Volume: 348, Issue:2-3
[125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.74 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index51.48 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
octreotide
[no description available]		4.9870
bim 23268
[no description available]		3.0910
seglitide
seglitide: more potent than somatostatin for inhibition of insulin, glucagon & growth hormone release; used experimentally in treatment of Alzheimer's disease; somatostatin receptor antagonist		4.9870
cgp 23996
CGP 23996: nonreducible analog of somatostatin; used to test binding sites for somatostatin		4.0140
prosomatostatin
[no description available]		4.9870heterodetic cyclic peptide;
peptide hormone		fungal metabolite;
mouse metabolite;
rat metabolite
ConditionIndicatedRelationship StrengthStudiesTrials